An experimental therapy for chronic obstructive pulmonary disease (COPD) which combines three compounds into single treatment has delivered statistically significant results in a Phase 3 trial, according to AstraZeneca Plc. ---Subscribe to MedNous to access this article--- Company News Clinical Research
